Arcellx Inc
ACLX
Mkt cap
$6.73B
EV/Sales
298.5
P/E ratio
—
FY2025 Revenue
$22.29M
EPS (9mo ended 2025-09-30)
−$3.06
Gross Margin (FY2025)
—
Profit Margin (FY2025)
−1027.25%
Beta
—
Div yield
—
Sector
Healthcare
What matters now, from SEC filings and analyst ratings
Takeaway
A takeaway appears here once the latest filing has been analyzed.
Analysts
Sector-relative grades for valuation, growth, profitability, momentum and revisions
Form 4 trades, last 90 days
No open-market insider buy or sell of ACLX since Aug 20, 2026.
Latest SEC filings
No recent SEC filings on file.
Latest stored headlines
Arcellx Inc (ACLX) is a biotechnology company listed on NASDAQ.
Latest reported ACLX revenue for 2025-12-31 was $22.3M. Net income was -$228.9M. Revenue was down 79.4% from 2024-12-31 to 2025-12-31. ACLX currently screens at market cap $6.73B.
Use this ACLX research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full ACLX income, balance, and cash tables.
Arcellx Inc (ACLX) is a biotechnology company in the Healthcare sector.
Latest cached Arcellx Inc (ACLX) revenue for Dec 31, 2025 was $22.3M. Net income was -$228.9M. Statements: https://lician.com/financials/aclx
Arcellx Inc (ACLX) market capitalization is $6.73B on the latest cached snapshot.
SEC filings · latest fiscal year FY2025
Free shows the newest 2 years. FY2021–FY2023 on Pro
−79.4%
Revenue growth year over year
Institutional holders from SEC 13F filings
10-Q results and the earnings calendar
Revenue and EPS are GAAP diluted from the 10-Q. Beat or miss compares the calendar's actual with its estimate on the same basis (adj.), or revenue with the revenue estimate.